OptiPlex Commercial feasibility of a cell-free reactor setup for optimisation of complex enzymatic pathways
- Coordinator
- Stichting Radboud Universiteit, Netherlands
- Runs
- 1 July 2022 to 31 December 2023
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069237
What the project is doing
In the project's own words, from its summary on CORDIS.
This project will explore the commercial feasibility of the first continuous stirred tank reactor solution for the synthetic replication and optimisation of complex enzymatic pathways. Our technology provides an urgently needed alternative for bioengineered organisms. Where normally raw materials of varying quality, competition between intermediates, toxicity, complex networks of feedback loops and other poorly understood factors limit production rates, our approach can be used to converge effectively to optimised biochemistry .As part of the project, we will establish two industrially relevant pathways, advance the software solution of our platform and develop a commercialisation strategy.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Radboud Universiteit | Nijmegen | Netherlands | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI